Abstract: A reverse acting rupture disc is provided having a laser defined electropolished line-of-weakness recess, and an improved method of forming an electropolished line-of-weakness recess in a reverse acting rupture disc that assures full opening of the disc upon reversal. A rupture disc blank is pre-bulged, final bulged, and then provided with a layer of resist material. A laser is used to remove at least a portion of the layer of resist material corresponding to a desired line-of-weakness recess in the concave face of the bulged rupture disc. The disc is then subjected to an electropolishing operation to remove metal from the lased area of the rupture disc, thereby forming a lustrous polished line-of-weakness recess in the disc of desired configuration and of a predetermined depth that is related to material thickness.

Abstract: A battery system for use in a vehicle is disclosed. The battery system includes a tray having a plurality of battery receptacles. A plurality of batteries are also provided, each battery in the plurality of batteries being received in a battery receptacle. A conductive layer in electrical communication with the plurality of batteries and a terminal for electrically coupling to a vehicle are also provided in the battery system. A cover interlocks with the tray. The cover carries a computer and a diagnostic identification system for the plurality of batteries. A housing for a battery system and a vehicle including a battery system are also disclosed.

Abstract: In order to maintain adequate bond strength of a composite in which a gas barrier coating comprising a clay dispersion and a polymer solution or dispersion of a PVA and/or EVA is positioned between two flexible plastics films using an adhesive, it is necessary that the clay dispersion and the polymer solution or dispersion should be kept separate until shortly before they are to be applied.

Abstract: An occupancy sensing system includes a vacate input to cause the system to turn lights on without substantial delay when a monitored space becomes occupied after turning the load off in response to the vacate input. A special vacate input may be eliminated by determining, in response to a manual-off input, if the space has been vacated. A dead time may be included to prevent the lights from being turned back on by movement that is detected as occupants vacate the monitored space after pressing a vacate or manual-OFF button.

Abstract: The present invention provides a microfluidic devices and methods of use thereof for the concentration and capture of cells. A pulsed non-Faradic electric field is applied relative to a sample under laminar flow, which results to the concentration and capture of charged analyte. Advantageously, pulse timing is selected to avoid problems associated with ionic screening within the channel. At least one of the electrodes within the channel is coated with an insulating layer to prevent a Faradic current from flowing in the channel. Under pulsed application of a unipolar voltage to the electrodes, charged analyte within the sample is moved towards one of the electrodes via a transient electrophoretic force.

Abstract: The present invention generally relates to orally administered pharmaceutical compositions of iron compounds with medium chain fatty acid salts. The invention further relates to methods of using the pharmaceutical compositions to treat iron deficiency and related disorders.

Abstract: There is provided an optical fiber cable having a plurality of optical fiber members. Each optical fiber member includes an optical fiber and a protective coating surrounding the optical fiber. A polymer coating surrounds the plurality of optical fiber members and a portion of the polymer coating is located between at least some of the optical fiber members. The optical fiber members and the polymer coating form an optical fiber unit. A tight buffer surrounds the optical fiber unit.

Abstract: The present invention provides pharmaceutical compositions for oral administration comprising a therapeutically effective amount of a selective factor Xa inhibitor or a pharmaceutically acceptable salt thereof and an enhancer, wherein the enhancer is a medium chain fatty acid or a salt, ester, ether, or derivative of a medium chain fatty acid and has a carbon chain length of from 4 to 20 carbon atoms. The present invention also provides a method for obtaining a reproducible bioavailability of selective factor Xa inhibitor in a subject after oral administration comprising orally administering a pharmaceutical composition as described above.

Abstract: The present invention provides assays and methods of compensating for changes in an assay where such changes are due to variations in a perturbing variable. This is achieved by a two-step method, the first step of which involves measurements of the dose-response curve, and thus the individual assay parameters, at different values of the perturbing variable. In the second step, unknown samples are assayed simultaneously with a standard. During this measurement, the value of the perturbing variable is unknown and the dose-response curve is therefore also unknown. The dose-response curves from the first step are used to determine a mathematical relationship between the assay parameters and the assay signal of the standard. Assay parameters that are valid for the unknown value of the perturbing variable can be obtained by substituting the value of the assay signal from the standard into the mathematical relationship and solving for the assay parameters.

Abstract: Assays and methods of compensating for changes in a dose-response curve of an assay due to variations in a perturbing variable by firstly measuring the dose-response curve, the individual assay parameters, at different values of the perturbing variable. Next, unknown samples are assayed simultaneously with a known standard at a chosen analyte concentration with a value of the perturbing variable being unknown and the dose-response curve unknown. The different dose-response curves from the first step are used to determine a mathematical relationship between assay parameters and the assay signal of the known standard. The assay parameters that are valid for the unknown value of the perturbing variable can be obtained by substituting the value of the assay signal from the known standard into the mathematical relationship and solving for the assay parameters.

Abstract: The present invention provides a microplate-based assay kit that incorporates all assay reagents and standards in a simple and efficient format and may be used in biochemical assays. The assay kit includes pre-filled, pre-sealed and barcoded microplates with a standard physical footprint for use in a microplate-based automated analyzer system which enables simple and efficient operation by an unskilled user via per-use factory-sealed and barcoded reagent and calibrator microplates. Such microplates allow the user to run a broad test menu without the need to monitor the arrangement and supply of internally stored reagents and standards, thus greatly simplifying the user experience and eliminating the need for highly skilled users.

Abstract: The present invention includes methods for preventing endometrial hyperplasia associated with estrogen therapy through the administration of a progestin agent. The methods presented may include starting the administration of a progestin agent at a high dose, and then lowering the dose.

Abstract: An electrical power pack may include a first power switch and a cycle control to cycle between the first power switch and a second power switch. An electrical power pack may include a first power switch and a delay element to delay an operation of the first power switch. A power pack system may include a first power switch to operate in response to a constant-on control and a second power switch to operate in response to an automatic control. A power pack system may include a first power switch to operate in response to a manual-on control, and a second power switch to operate in response to an automatic-on control.

Abstract: The present invention provides pharmaceutical compositions for oral administration comprising a therapeutically effective amount of a selective factor Xa inhibitor or a pharmaceutically acceptable salt thereof and an enhancer, wherein the enhancer is a medium chain fatty acid or a salt, ester, ether, or derivative of a medium chain fatty acid and has a carbon chain length of from about 4 to about 20 carbon atoms. The present invention also provides a method for obtaining a reproducible bioavailability of selective factor Xa inhibitor in an object after oral administration comprising orally administering a pharmaceutical composition as described above.

Abstract: An electrical power pack may include a first power switch and a cycle control to cycle between the first power switch and a second power switch. An electrical power pack may include a first power switch and a delay element to delay an operation of the first power switch. A power pack system may include a first power switch to operate in response to a constant-on control and a second power switch to operate in response to an automatic control. A power pack system may include a first power switch to operate in response to a manual-on control, and a second power switch to operate in response to an automatic-on control.

Abstract: A method and system increase processed specimen yield in the laser processing of target material that includes multiple specimens formed on a common substrate. Preferred embodiments implement a feature that enables storage in the laser processing system a list of defective specimens that have somehow been subject to error during laser processing. Once the common substrate has been completely processed, the system alerts an operator to the number of improperly processed specimens and gives the operator an opportunity to run a software routine, which in a preferred embodiment uses a laser to scribe a mark on the top surface of each improperly processed specimen.

Abstract: The present invention provides pharmaceutical compositions which are effective in providing therapeutically effective blood levels of a therapeutically active ingredient to a subject when administered to a gastrointestinal tract. In one aspect, the pharmaceutical compositions comprise a therapeutically effective amount of a therapeutically active ingredient; at least one water soluble enhancer, e.g., a medium chain fatty acid or a salt, ester, ether, or derivative of a medium chain fatty acid and has a carbon chain length of from about 4 to about 20 carbon atoms; and a saccharide.

Abstract: A wireless demand response endpoint includes a power switch and a wireless receiver to control the power switch in response to a wireless demand signal. The wireless demand signal may be transmitted at the same premises as the endpoint. One or more wireless endpoints at the premises may be configured to respond to the wireless demand signal. The wireless demand signal may be transmitted automatically, manually, or in other modes. Power switching may be on/off, dimming, etc.

Abstract: A fiber optic connector for use with a fiber optic network having at least one predetermined operating wavelength is provided. First housing contains at least one optical fiber. The optical fiber has a free end forming a physical contact. The physical contact is coated with a protective film. The optical thickness of the protective film is at least 0.10 of the operating wavelength of the fiber optic network. Preferably, the physical contact is thermally shaped. Also preferably, the optical fiber is attached to a quick connect device forming a termini. The physical contact of the optical fiber can be readily coated with the protective film by placing the termini in a vacuum chamber.

Abstract: The invention relates to a pharmaceutical composition and oral dosage forms comprising a bisphosphonate in combination with an enhancer to enhance intestinal delivery of the bisphosphonate to the underlying circulation. Preferably, the enhancer is a medium chain fatty acid or a medium chain fatty acid derivative having a carbon chain length of from 6 to 20 carbon atoms, and the solid oral dosage form is a controlled release dosage form such as a delayed release dosage form.